Search clinical trials for: Recombinant+human+hyaluronidase

Total 5125 results

Halozyme Therapeutics
Baxter Healthcare Corporation

Completed

Subcutaneous Rehydration Compared to Intravenous Rehydration (PEDs-II)

Dehydration

United States
Halozyme Therapeutics
Baxter Healthcare Corporation

Completed

Study of Subcutaneous Hydration Enabled by Human Recombinant Hyaluronidase (Hylenex) (INFUSE-NSLR)

Healthy

United States
Stanford University
National Cancer Institute (NCI)

Terminated

Recombinant Human Hyaluronidase in Treating Lymphedema in Patients With Cancer

Lymphedema | Malignant Neoplasm

United States
Eisai Inc.
Halozyme Therapeutics

Terminated

Study of Eribulin Mesylate in Combination With PEGylated Recombinant Human Hyaluronidase (PEGPH20) Versus Eribulin Mesylate Alone in Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC)

Metastatic Breast Cancer

United States
Baxter Healthcare Corporation
PPD; Halozyme Therapeutics

Completed

Study of Subcutaneous Rehydration With Recombinant Human Hyaluronidase for Infants and Children (INFUSE-PR)

Dehydration
Tissa Hata, MD

Completed

Effects of Subcutaneous Hyaluronidase Administration on Psoriatic Plaques

Psoriasis

United States
Massachusetts General Hospital
Baxter Healthcare Corporation

Completed

EASI Access II --- Follow-up Study to the EASI Access Trial

Disaster Medicine | Dehydration | Difficult Intravenous Access

United States
Halozyme Therapeutics

Completed

CONSISTENT 1: Metabolic and Safety Outcomes of Hylenex Recombinant (Hyaluronidase Human Injection) Preadministered at CSII Infusion Site in Participants With Type 1 Diabetes Mellitus (T1DM)

Type 1 Diabetes Mellitus

United States
Baxalta now part of Shire

Completed

Study to Determine the Dose of Recombinant Human Hyaluronidase Needed to Infuse a Full Dose of IGIV Subcutaneously

Primary Immunodeficiency Diseases (PID)

United States
Vanderbilt University Medical Center
Baxter Healthcare Corporation

Completed

Descriptive Study of Cardiac Output During Rehydration With Recombinant Human Hyaluronidase in Pediatrics (Hylenex)

Dehydration | Pediatrics | Cardiac Output

United States
BMI Korea

Completed

Evaluate the Safety and Tolerability of a Single-dose Administration of BMI2004 Inj.

Health, Subjective

Korea, Republic of
Halozyme Therapeutics

Completed

A Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab in Participants With Selected Hyaluronan High Solid Tumors

Gastric Cancer | NSCLC

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Withdrawn

Pembrolizumab and PEGPH20 in Treating Patients With Metastatic Pancreatic Cancer

Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Adenocarcinoma

United States
Baxter Healthcare Corporation
Halozyme Therapeutics

Terminated

Study of In-line Pressure Using Various Techniques of Subcutaneous Administration of Fluids Enabled by Human Recombinant Hyaluronidase (INFUSE-AT1A) (INFUSE-AT1A)

Dehydration

United States
University of Southern California
National Cancer Institute (NCI); Genentech, Inc.

Recruiting

Subcutaneous Atezolizumab for the Treatment of Non-small Cell Lung Cancer

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Lung Non-Small Cell Carcinoma | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung... and other conditions

United States
Takeda

Completed

A Study of TAK-771 in Japanese People With Primary Immunodeficiency Diseases (PID)

Primary Immunodeficiency Diseases (PID)

Japan
PH Research, S.L.

Terminated

A Trial of PEGPH20 in Combination With Avelumab in Chemotherapy Resistant Pancreatic Cancer

Pancreatic Cancer | Pancreatic Ductal Adenocarcinoma

Spain
Massachusetts General Hospital
Baxter Healthcare Corporation

Completed

Recombinant Hyaluronidase in Out-of-Hospital Setting: The EASI Access Trial

Dehydration | Mass Casualty Incident

United States
Takeda

Active, not recruiting

A Study to Evaluate the Long-term Safety of TAK-771 in Japanese Primary Immunodeficiency Disease (PID) Participants

Primary Immunodeficiency Diseases (PID)

Japan
Takeda

Active, not recruiting

A Study of TAK-771 in Japanese Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) and Multifocal Motor Neuropathy (MMN)

Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | Multifocal Motor Neuropathy (MMN)

Japan
Janssen Research & Development, LLC

Completed

A Study of Daratumumab With the Addition of Recombinant Human Hyaluronidase (rHuPH20) for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

United States, Spain, Netherlands, Sweden, Denmark, France
GWT-TUD GmbH

Completed

Facilitated Immunoglobulin Administration Registry and Outcomes Study (FIGARO) (FIGARO)

Primary Immunodeficiency | Secondary Immune Deficiency

Germany, Italy, France
Halozyme Therapeutics

Completed

Pharmacokinetic (PK), Pharmacodynamic (PD), and Safety Study of Subcutaneously Administered Humalog® With and Without Recombinant Human Hyaluronidase (rHuPH20)and Humulin-R® With and Without rHuPH20

Diabetes Mellitus

United States
Shandong University
Shandong Provincial Hospital; The First Affiliated Hospital of Dalian Medical...

Completed

An Investigation of rhTPO With Different Frequencies in the Management of ITP

Immune Thrombocytopenia

China
Baxalta now part of Shire
Takeda Development Center Americas, Inc.

Completed

Long-Term Tolerability and Safety of HYQVIA/HyQvia in CIDP

Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Spain, Canada, Poland, Italy, Serbia, Germany, Mexico, Turkey, United Kingdom, Czechia, France, United States, Argentina, Brazil, Colombia, Denmark, Greece, Slovakia
Halozyme Therapeutics

Completed

Phase II Pharmacokinetics Study of Humalog and Humulin-R With and Without rHuPH20 in Type 1 Diabetes Mellitus

Type 1 Diabetes Mellitus

United States
Halozyme Therapeutics

Completed

Randomized, Double-blind, Crossover, Pharmacokinetic (PK) and Glucodynamic (GD) Study of Continuous Subcutaneous Insulin Infusion (CSII) in Participants With Type 1 Diabetes Mellitus (T1DM)

Type 1 Diabetes Mellitus

United States
Peking Union Medical College
Shenyang Sunshine Pharmaceutical Co., LTD.

Unknown

Efficacy and Safety Study of Maintenance Treatment With rhTPO in Thrombocytopenic Subjects With ITP

Thrombocytopenia | Immune Thrombocytopenia | Idiopathic Thrombocytopenic Purpura

China
Massachusetts General Hospital

Completed

Recombinant Human Prolactin for Lactation Induction

Lactation

United States
Halozyme Therapeutics

Completed

Pharmacokinetic and Glucodynamic Crossover Study of Subcutaneously (SC) Administered Insulin Lispro + Recombinant Human Hyaluronidase (rHuPH20) and Regular Human Insulin + rHuPH20 Compared to Insulin Lispro Alone

Diabetes Mellitus

United States
Tianjin Medical University General Hospital

Unknown

Efficacy and Safety of Thrombopoietin In Patients With Severe and Very Severe Aplastic Anemia

Anemia, Aplastic

China
Alexion Pharmaceuticals, Inc.

Completed

Pharmacokinetic Study of Ravulizumab Administered Subcutaneously With Recombinant Human Hyaluronidase PH20 (rHuPH20) in Healthy Adult Volunteers

Healthy

United Kingdom
Baxalta now part of Shire

Completed

Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD

Primary Immunodeficiency Diseases (PID)

United States
Steen Bonnema

Completed

rhTSH, Radioiodine Uptake and Goiter Reduction Following 131I Therapy in Patients With Benign Nontoxic Nodular Goiter

Nodular Goiter

Denmark
Halozyme Therapeutics

Terminated

A Phase 1b Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Docetaxel in Subjects With Recurrent Previously Treated Locally Advanced or Metastatic NSCLC (PRIMAL)

Non-small Cell Lung Cancer

United States
Thomas Jefferson University
Janssen Scientific Affairs, LLC

Active, not recruiting

Home Based Daratumumab Administration for Patients With Multiple Myeloma

Plasma Cell Myeloma

United States
Halozyme Therapeutics

Completed

Liquid Meal Study With Insulin Lispro With/Without Recombinant Human Hyaluronidase PH20 (rHuPH20) and Regular Human Insulin With rHuPH20 to Compare Pharmacokinetics, Postprandial Glycemic Response, and Optimal Insulin Dose in Participants With Type 2 Diabetes Mellitus (T2DM)

Diabetes Mellitus, Type 2

United States
Takeda
Takeda Development Center Americas, Inc.

Not yet recruiting

A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodeficiency Diseases

Primary Immunodeficiency Diseases (PID)
Takeda
Takeda Development Center Americas, Inc.; Baxalta Innovations GmbH, now part...

Completed

A Study of TAK-881 in Healthy Adults

Healthy Volunteers

United States
Ottawa Hospital Research Institute
Canadian Institutes of Health Research (CIHR); Stem Cell Network

Active, not recruiting

The Enhanced Angiogenic Cell Therapy - Acute Myocardial Infarction Trial (ENACT-AMI)

Anterior Wall Myocardial Infarction

Canada
Massachusetts General Hospital

Withdrawn

Recombinant Human Prolactin for Lactation Induction

Lactation

United States
Hongnan Mo

Unknown

Recombinant Human Thrombopoietin for Mobilization of Peripheral Blood Progenitor Cells for Autologous Transplantation

Hematopoietic Stem Cell Transplantation | Thrombocytopoietin | Hematopoietic Stem Cell Mobilization

China
Massachusetts General Hospital

Completed

The Safety and Efficacy of Recombinant Human Prolactin

Healthy

United States
Massachusetts General Hospital

Completed

Recombinant Human Prolactin for Lactation Induction

Lactation

United States
University of Milan
Eli Lilly and Company

Unknown

Evaluation of rhGH Replacement Therapy in Patients With Pseudohypoparathyroidism Type Ia (PHP Ia)

Growth Hormone Deficiency, Dwarfism | Pseudohypoparathyroidism

Italy
Baxalta now part of Shire
Baxalta Innovations GmbH, now part of Shire

Completed

A Study to Assess the Tolerability, Safety, and Pharmacokinetics of Subcutaneous Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) With Ramp-up and No Ramp-up Dosing in Healthy Adult Participants

Healthy Volunteers

United States
Protgen Ltd

Completed

Recombinant Human Serum Albumin in Healthy Subjects

Hepatic Ascites

China
Protgen Ltd

Completed

Phase II/III of Recombinant Human Serum Albumin

Hepatic Ascites

China
The First Hospital of Jilin University

Completed

Phase Ib of Recombinant Human Albumin Injection

Ascites

China
Shire
Halozyme Therapeutics

Completed

A Study to Evaluate the Safety and Pharmacology of Subcutaneous Administration of CINRYZE With Recombinant Human Hyaluronidase

Hereditary Angioedema

United States

3

Subscribe